Skip to main content
[Preprint]. 2024 Aug 21:2024.08.19.608619. [Version 1] doi: 10.1101/2024.08.19.608619

Figure 1: Summary of the SARS-CoV-2 nsp3-mac1 campaign.

Figure 1:

(A) Schematic of the role of viral nsp3-mac1 in reversing ADP-ribosylation via innate immune response. (B) We report a rapid fragment-to-lead campaign, realising significant strides in potency. The inset shows the structure of a lead compound (ASAP-0008327), confirming active site engagement (PDB ID 7GZU).